$DCPH News
Last published 1y ago
- 1y agoDCPHDeciphera Pharmaceuticals, LLC - Appeal, AffirmedUS Patent Trial and Appeal Board
- 2y agoDCPHOno Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)PR NewswireOno Pharmaceutical, Co., Ltd. (Chairman and CEO: Gyo Sagara, "Ono") today announced that it has successfully completed the tender offer, previously...
- 2y agoHIBBCRGYDCPHHCPKuehn Law Encourages HIBB, CRGY, DCPH, and HCP Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoDCPHDeciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The LancetBusiness Wire– MOTION Phase 3 Data Demonstrate Robust Efficacy, Clinically Meaningful Improvements in Quality-of-Life Measures, and Well-Tolerated Safety Profile, Positioning Vimseltinib as Potential New TGCT Treatment – – Company
- 2y agoDCPHHTLFTBNKUMBFKuehn Law Encourages UMBF, HTLF, TBNK, and DCPH Investors to Contact Law FirmGlobeNewswireNEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoDCPHONO Enters into a Definitive Agreement to Acquire Deciphera PharmaceuticalsPR NewswireONO Pharmaceutical, Co., Ltd., (TSE: 4528, Representative Director, Chairman of the Board and Chief Executive Officer: Gyo Sagara, "ONO") and...
- 2y agoDCPHDeciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 BillionBusiness WireDeciphera Shareholders to Receive $25.60 per Share in Cash Deciphera's Kinase Inhibitor Expertise and Established Commercialization Platform in Key Markets Will Reinforce ONO Pharmaceutical's Pipeline and Accelerate
- 2y agoDCPHDeciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology ForumBusiness WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that
- 2y agoDCPHDeciphera Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that
- 2y agoDCPHDeciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial ResultsBusiness Wire– Fourth Quarter 2023 Total Revenue of $48.3 Million and Full Year 2023 Revenue of $163.4 Million; QINLOCK® Net Product Revenue Increased 27% to $159.1 Million in 2023 Compared to 2022 – – Expects to Submit NDA
- 2y agoDCPHDeciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024Business WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that
- 2y agoDCPHDeciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceBusiness WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that
- 2y agoDCPHDeciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers SymposiumBusiness Wire– Median Overall Survival for QINLOCK® of 35.5 Months Versus 31.5 Months for Sunitinib in the All-Patient Intent-to Treat-Population – – Long-Term Safety Profile Consistent with Primary Analysis Showing Fewer
- 2y agoDCPHDeciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product CompanyBusiness Wire– Preliminary Unaudited Fourth Quarter 2023 QINLOCK® Net Product Revenue of Approximately $46.0 Million, an Increase of 40% Compared to the Fourth Quarter of 2022 – – Expects to Submit Vimseltinib New Drug
- 2y agoDCPHDeciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18Business Wire– Median Progression-Free Survival for QINLOCK® of 14.2 Months Versus 1.5 Months for Sunitinib – – Objective Response Rate of 44.4% for QINLOCK Versus 0% for Sunitinib – – Median Overall Survival for QINLOCK
- 2y agoDCPHDeciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceBusiness WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that
- 2y agoDCPHDeciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology SummitBusiness WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that
- 3y agoDCPHDeciphera Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that
- 3y agoDCPHDeciphera Pharmaceuticals Announces Third Quarter 2023 Financial ResultsBusiness Wire– Third Quarter 2023 Total Revenue of $43.3 Million; Net Product Revenue for QINLOCK® (ripretinib) Increased 29% to $41.8 Million Compared to Third Quarter 2022 – – Announced Positive Top-line Results for MOTION
- 3y agoDCPHDeciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCTBusiness Wire– MOTION Study Met Primary Endpoint with Objective Response Rate (ORR) at Week 25 of 40% Compared to 0% for Placebo (p<0.0001) – – MOTION Study Met All Key Secondary Endpoints with Statistically Significant and
- 3y agoDCPHMedison Pharma Announces Public Formulary Listing of QINLOCK® (ripretinib) in Canadian Provinces: Ontario and Quebec for Advanced Gastrointestinal Stromal Tumor (GIST) TreatmentPR NewswireThis marks a significant step forward in the multi-regional partnership between Deciphera and Medison ZUG, Switzerland and TORONTO, Sept. 29, 2023 /CNW/ -- Today, Medison Pharma ("Medison"), a global pharma
- 3y agoDCPHDeciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that
- 3y agoDCPHDeciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that
- 3y agoDCPHDeciphera Pharmaceuticals, Inc. (DCPH) Q2 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoDCPHDeciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023Business WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that
- 3y agoDCPHDeciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual MeetingBusiness Wire– Company Presents Poster on Overall Survival and Long-Term Safety Results from INTRIGUE Study; Second Poster Presents Analysis from INTRIGUE Patients without Detectable ctDNA at Baseline – – Encore Oral Presentation
- 3y agoDCPHDeciphera Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that
- 3y agoDCPHDeciphera Pharmaceuticals to Present at the JMP Securities Life Sciences ConferenceBusiness WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that
- 3y agoDCPHDeciphera Pharmaceuticals Announces First Quarter 2023 Financial ResultsBusiness Wire– First Quarter 2023 Total Revenue of $33.4 Million; Net Product Revenue for QINLOCK® Increased 15% to $33.2 Million Compared to First Quarter 2022 – – Enrollment Complete in the MOTION Pivotal Phase 3 Study of
- 3y agoDCPHDeciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023Business WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that
- 3y agoDCPHDeciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology DaysBusiness WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that
- 3y agoDCPHDeciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18Business Wire– NCCN Guidelines Include QINLOCK as a Preferred Regimen for Second-Line GIST Patients Intolerant to Sunitinib – – Breakthrough Therapy Designation is Based on Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical
- 3y agoDCPHDeciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023Business Wire– First Preclinical Data for Pan-RAF Inhibitor DCC-3084 to be Presented; IND Filing Expected in Second Half of 2023 – – New Preclinical Data Supports ULK inhibitor DCC-3116 in Combination with QINLOCK® in GIST and
- 3y agoDCPHDeciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCTBusiness Wire– Top-line Results Expected in the Fourth Quarter of 2023 – – Phase 1/2 Data Demonstrated Vimseltinib's Best-in-Class Potential for the Treatment of TGCT – Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a
- 3y agoDCPHDeciphera Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that
- 3y agoDCPHA Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib - NCT05734105ClinicalTrials.govProgression-free Survival (PFS), Objective Response Rate (ORR), Overall Survival (OS)
- 3y agoDCPHDeciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial ResultsBusiness Wire– Fourth Quarter 2022 Total Revenue of $36.3 Million and Full Year 2022 Revenue of $134.0 Million; QINLOCK® Net Product Revenue Increased 44% to $125.5 Million in 2022 Compared to 2021 – – Expects to Complete
- 3y agoDCPHDeciphera Pharmaceuticals to Participate in Upcoming Investor ConferencesBusiness WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that
- 3y agoDCPHDeciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023Business WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that
- 3y agoDCPHDeciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the
- 3y agoDCPHDeciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series SessionBusiness Wire– Second-Line GIST Patients with Mutations in KIT Exon 11 + 17/18 Only Demonstrated Substantial Clinical Benefit from QINLOCK® but Not Sunitinib – – Company Plans to Initiate the INSIGHT Pivotal Phase 3 Clinical
- 3y agoDCPHDeciphera Pharmaceuticals Announces Pricing of Public Offering of Common StockBusiness WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the
- 3y agoDCPHDeciphera Pharmaceuticals Announces Proposed Public Offering of Common StockBusiness WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that
- 3y agoDCPHDeciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product CompanyBusiness Wire– Plans to Initiate Pivotal Phase 3 INSIGHT Study of QINLOCK® Versus Sunitinib in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only in the Second Half of 2023 Based on ctDNA Analysis from
- 3y agoDCPHDeciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 OnlyBusiness Wire– Median Progression Free Survival for QINLOCK of 14.2 Months Versus Sunitinib of 1.5 Months; Hazard Ratio of 0.22, nominal p value <0.0001 – – Objective Response Rate of 44.4% for QINLOCK Versus 0% for Sunitinib;
- 3y agoDCPHDeciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare ConferenceBusiness WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at
- 3y agoDCPHDeciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology SummitBusiness WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit
- 4y agoDCPHDeciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor ConferencesBusiness WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that members of the management team will participate in fireside chats at the following investor conferences: Stifel Healthcare Conference on Tuesday,
- 4y agoDCPHDeciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial ResultsBusiness Wire– Third Quarter 2022 Total Revenue of $36.0 Million; QINLOCK® Net Product Revenue Increases 49% to $32.3 Million Compared to Third Quarter 2021 – – Presented Updated Results from Phase 1/2 Study of Vimseltinib in
- 4y agoDCPHDeciphera Pharmaceuticals, Inc. to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022Business WireDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that